Evidence map›Paper›PMID 33801579›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Comprehensive and Rapid Quality Evaluation Method for the Ayurvedic Medicine Divya-Swasari-Vati Using Two Analytical Techniques: UPLC/QToF MS and HPLC-DAD.

Acharya Balkrishna, Sudeep Verma, Priyanka Sharma, Meenu Tomer, Jyotish Srivastava, Anurag Varshney

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Metabolomics andHeliyon · 2024
    Article
  5. The Cardiorenal Effects ofPharmaceuticals (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Penta-O-Galloyl-Frontiers in pharmacology · 2022
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Acharya BalkrishnaDrug Discovery and Development Division, Patanjali Research Institute, Haridwar 249 405, Uttarakhand, India.
Sudeep VermaDrug Discovery and Development Division, Patanjali Research Institute, Haridwar 249 405, Uttarakhand, India.
Priyanka SharmaDrug Discovery and Development Division, Patanjali Research Institute, Haridwar 249 405, Uttarakhand, India.
Meenu TomerDrug Discovery and Development Division, Patanjali Research Institute, Haridwar 249 405, Uttarakhand, India.
Jyotish SrivastavaDrug Discovery and Development Division, Patanjali Research Institute, Haridwar 249 405, Uttarakhand, India.
Anurag VarshneyDrug Discovery and Development Division, Patanjali Research Institute, Haridwar 249 405, Uttarakhand, India.ORCID 0000-0001-8509-0882
Patanjali Research Foundation · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Divya-Swasari-Vati (DSV) is a calcium-containing herbal medicine formulated for the symptomatic control of respiratory illnesses observed in the current COVID-19 pandemic. DSV is an Ayurvedic medicine used for the treatment of chronic cough and inflammation. The formulation has shown its pharmacological effects against SARS-CoV-2 induced inflammation in the humanized zebrafish model. The present inventive research aimed to establish comprehensive quality parameters of the DSV formulation using validated chromatographic analytical tools. Exhaustive identification of signature marker compounds present in the plant ingredients was carried out using ultra performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC/QToF MS). This was followed by simultaneous estimation of selected marker components using rapid and reliable high-performance liquid chromatography (HPLC) analysis. Eleven marker components, namely gallic acid, protocatechuic acid, methyl gallate, ellagic acid, coumarin, cinnamic acid, glycyrrhizin, eugenol, 6-gingerol, piperine and glabridin, were selected out of seventy-four identified makers for the quantitative analysis in DSV formulation. Validation of the HPLC method was evaluated by its linearity, precision, and accuracy tests as per the International Council of Harmonization (ICH) guidelines. Calibration curves for the eleven marker compounds showed good linear regression (

Indexed as

AyurvedaDivya-Swasari-Vatiherbal medicineHPLCUPLC/QToF MSvalidation

Identifiers

PMID33801579
PMCPMC8067215
OpenAlexW3140814525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.